419 related articles for article (PubMed ID: 36077477)
1. Hyperthermic Intraperitoneal Chemotherapy (HIPEC): An Overview of the Molecular and Cellular Mechanisms of Actions and Effects on Epithelial Ovarian Cancers.
Lim PQ; Han IH; Seow KM; Chen KH
Int J Mol Sci; 2022 Sep; 23(17):. PubMed ID: 36077477
[TBL] [Abstract][Full Text] [Related]
2. Hyperthermic Intraperitoneal Chemotherapy After Interval Cytoreductive Surgery for Patients With Advanced-Stage Ovarian Cancer Who Had Received Neoadjuvant Chemotherapy.
Lee JY; Lee YJ; Son JH; Kim S; Choi MC; Suh DH; Song JY; Hong DG; Kim MK; Kim JH; Chang SJ
JAMA Surg; 2023 Nov; 158(11):1133-1140. PubMed ID: 37672264
[TBL] [Abstract][Full Text] [Related]
3. Cytoreductive Surgery (CRS) Combined With Hyperthermic Intraperitoneal Chemotherapy (HIPEC) for Platinum-Sensitive Recurrence Epithelial Ovarian Cancer With HRR Mutation: A Phase III Randomized Clinical Trial.
Qi Y; Zhang Y; Shi Y; Yao S; Dai M; Cai H
Technol Cancer Res Treat; 2022; 21():15330338221104565. PubMed ID: 35929135
[No Abstract] [Full Text] [Related]
4. Prognostic value and adverse events of cytoreductive surgery with hyperthermic intraperitoneal chemotherapy in primary advanced and platinum-sensitive recurrent epithelial ovarian cancer: a systematic review and meta-analysis.
Xia Y; Wang H; Zhang J; Wang Y
Int J Hyperthermia; 2023; 40(1):2165729. PubMed ID: 36775583
[TBL] [Abstract][Full Text] [Related]
5. Hyperthermic Intraperitoneal Chemotherapy in the Management of Primary Epithelial Ovarian Cancer: A Debated Issue for Gynecologic Oncologists.
Gadducci A; Cosio S; Lippolis PV
Anticancer Res; 2022 Oct; 42(10):4659-4665. PubMed ID: 36191972
[TBL] [Abstract][Full Text] [Related]
6. Hyperthermic intraperitoneal chemotherapy for recurrent epithelial ovarian cancer.
Chen WC; Huang HJ; Yang LY; Pan YB; Huang KG; Lin CT; Chen MY; Tang YH; Chang TC; Lai CH; Chou HH
Biomed J; 2022 Oct; 45(5):821-827. PubMed ID: 34656802
[TBL] [Abstract][Full Text] [Related]
7. Patterns of recurrence in women with advanced and recurrent epithelial ovarian cancer treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy.
Chambers LM; Yao M; Morton M; Gruner M; Chichura A; Horowitz M; Costales AB; Rose PG; Michener CM; Debernardo R
Gynecol Oncol; 2021 May; 161(2):389-395. PubMed ID: 33551202
[TBL] [Abstract][Full Text] [Related]
8. Survival After Hyperthermic Intraperitoneal Chemotherapy and Primary or Interval Cytoreductive Surgery in Ovarian Cancer: A Randomized Clinical Trial.
Lim MC; Chang SJ; Park B; Yoo HJ; Yoo CW; Nam BH; Park SY;
JAMA Surg; 2022 May; 157(5):374-383. PubMed ID: 35262624
[TBL] [Abstract][Full Text] [Related]
9. A retrospective analysis of secondary cytoreductive surgery plus hyperthermic intraperitoneal chemotherapy in patients with recurrent ovarian cancer.
Yang D; Zhang Y; Gong P; Liu F; Gan Y; Bai W
J Obstet Gynaecol Res; 2023 Jul; 49(7):1795-1804. PubMed ID: 37231941
[TBL] [Abstract][Full Text] [Related]
10. Critical Analysis of Stage IV Epithelial Ovarian Cancer Patients after Treatment with Neoadjuvant Chemotherapy followed by Cytoreductive Surgery and Hyperthermic Intraperitoneal Chemotherapy (CRS/HIPEC).
Munoz-Zuluaga CA; Sardi A; Sittig M; Gushchin V; King MC; Nieroda C; Lopez-Ramirez F; Diaz-Montes TP
Int J Surg Oncol; 2020; 2020():1467403. PubMed ID: 33381312
[TBL] [Abstract][Full Text] [Related]
11. Ten-year treatment outcomes of consolidation hyperthermic intraperitoneal chemotherapy for ovarian cancer (HIPEC-KOV-03R).
Yoo JG; Kim JH; Park EY; Kim I; Lim MC; Lee SJ
J Gynecol Oncol; 2023 Nov; 34(6):e72. PubMed ID: 37417300
[TBL] [Abstract][Full Text] [Related]
12. Pattern of recurrence after interval cytoreductive surgery and HIPEC following neoadjuvant chemotherapy in primary advanced stage IIIC/IVA epithelial ovarian cancer.
Sinukumar S; Damodaran D; Ray M; Mehta S; Paul L; Bhatt A
Eur J Surg Oncol; 2021 Jun; 47(6):1427-1433. PubMed ID: 33509612
[TBL] [Abstract][Full Text] [Related]
13. Hyperthermic Intraperitoneal Chemotherapy in Ovarian Cancer.
van Driel WJ; Koole SN; Sikorska K; Schagen van Leeuwen JH; Schreuder HWR; Hermans RHM; de Hingh IHJT; van der Velden J; Arts HJ; Massuger LFAG; Aalbers AGJ; Verwaal VJ; Kieffer JM; Van de Vijver KK; van Tinteren H; Aaronson NK; Sonke GS
N Engl J Med; 2018 Jan; 378(3):230-240. PubMed ID: 29342393
[TBL] [Abstract][Full Text] [Related]
14. Hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) with primary or secondary cytoreductive surgery in the treatment of advanced epithelial ovarian cancer.
Manzanedo I; Pereira F; Pérez-Viejo E; Serrano Á; Hernández-García M; Martínez-Torres B; Rihuete-Caro C; Calzas J; Cueto M
Minerva Ginecol; 2017 Apr; 69(2):119-127. PubMed ID: 27415829
[TBL] [Abstract][Full Text] [Related]
15. Clinical Trial Protocol for HyNOVA: Hyperthermic and Normothermic intraperitoneal chemotherapy following interval cytoreductive surgery for stage III epithelial OVArian, fallopian tube and primary peritoneal cancer (ANZGOG1901/2020).
Farrell R; Burling M; Lee YC; Pather S; Robledo K; Mercieca-Bebber R; Stockler M;
J Gynecol Oncol; 2022 Jan; 33(1):e1. PubMed ID: 34783204
[TBL] [Abstract][Full Text] [Related]
16. Combined Interval Cytoreductive Surgery and Carboplatin-Based Hyperthermic Intraperitoneal Chemotherapy in Advanced Primary High-Grade Serous Ovarian Cancer.
Brault C; Brind'Amour A; de Guerke L; Auclair MH; Sideris L; Dubé P; Soucisse M; Tremblay JF; Bernard L; Piedimonte S; Fortin S
Curr Oncol; 2023 Dec; 30(12):10272-10282. PubMed ID: 38132382
[TBL] [Abstract][Full Text] [Related]
17. Hyperthermic Intraperitoneal Chemotherapy for Ovarian and Colorectal Cancer: A Review.
van Stein RM; Aalbers AGJ; Sonke GS; van Driel WJ
JAMA Oncol; 2021 Aug; 7(8):1231-1238. PubMed ID: 33956063
[TBL] [Abstract][Full Text] [Related]
18. Cytoreductive surgery and HIPEC in recurrent epithelial ovarian cancer: a prospective randomized phase III study.
Spiliotis J; Halkia E; Lianos E; Kalantzi N; Grivas A; Efstathiou E; Giassas S
Ann Surg Oncol; 2015 May; 22(5):1570-5. PubMed ID: 25391263
[TBL] [Abstract][Full Text] [Related]
19. HIPEC ROC I: a phase I study of cisplatin administered as hyperthermic intraoperative intraperitoneal chemoperfusion followed by postoperative intravenous platinum-based chemotherapy in patients with platinum-sensitive recurrent epithelial ovarian cancer.
Zivanovic O; Abramian A; Kullmann M; Fuhrmann C; Coch C; Hoeller T; Ruehs H; Keyver-Paik MD; Rudlowski C; Weber S; Kiefer N; Poelcher ML; Thiesler T; Rostamzadeh B; Mallmann M; Schaefer N; Permantier M; Latten S; Kalff J; Thomale J; Jaehde U; Kuhn WC
Int J Cancer; 2015 Feb; 136(3):699-708. PubMed ID: 24895230
[TBL] [Abstract][Full Text] [Related]
20. Effect of platinum sensitivity on the efficacy of hyperthermic intraperitoneal chemotherapy (HIPEC) in recurrent epithelial ovarian cancer.
Costales AB; Chambers L; Chichura A; Rose PG; Mahdi H; Michener CM; Yao M; Debernardo R
J Gynecol Obstet Hum Reprod; 2021 May; 50(5):101844. PubMed ID: 32590110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
